PeerView Oncology

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

PeerView Oncology

Basic Science
Genitourinary
Breast
Lung
Hematologic Oncology
Gastrointestinal
Events

Playback speed

10 seconds

Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in Clinical Benefit Between 1st Generation EGFR TKIs vs. Osimertinib?

By PeerView Oncology FEATURING Sandip Patel

388 views

May 15, 2020

Comments 0

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss

The First Treatment Choice Matters

Feat. A. Ip

Lung

Challenging Case of a 63 y/o Never-Smoking Female With TTF-1+ Lung A…

PeerView Oncology

E. Garon, J. Heymach

248 views

Locally Advanced and Early NSCLC IO Update: Will IO Change the Multi…

PeerView Oncology

B. Stiles

123 views

Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in C…

PeerView Oncology

S. Patel

388 views

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or C…

PeerView Oncology

S. Patel, M. Ahluwalia, K. Beal

18 views

64 y/o Female With Newly Diagnosed Stage 4 NSCLC, EGFR exon 19 Mutat…

PeerView Oncology

S. Patel, M. Ahluwalia, K. Beal

22 views

Management of EGFR-Mutant Lung Cancer With Central Nervous System Me…

PeerView Oncology

S. Patel, M. Ahluwalia, K. Beal

15 views

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Met…

PeerView Oncology

S. Patel, M. Ahluwalia, K. Beal

114 views